These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6949052)

  • 1. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R
    N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052
    [No Abstract]   [Full Text] [Related]  

  • 2. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
    Rabey JM; Treves T; Streifler M; Korczyn AD
    Adv Neurol; 1987; 45():569-72. PubMed ID: 3825734
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez Lage JM
    Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
    Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA
    Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic effect of lisuride in advanced Parkinson's disease.
    Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E
    Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of lisuride in severe Parkinson's disease.
    Chin D; Yu YL; Huang CY
    Clin Exp Neurol; 1986; 22():63-9. PubMed ID: 3581512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of terguride in patients with Parkinson's disease.
    Suchy I; Rinne UK; Wachtel H
    Adv Neurol; 1987; 45():577-81. PubMed ID: 3548267
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of ergot derivative lisuride in Parkinson's disease.
    Suchy I; Horowski R
    Adv Neurol; 1984; 40():515-21. PubMed ID: 6695629
    [No Abstract]   [Full Text] [Related]  

  • 12. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 13. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
    Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D
    Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral administration of lisuride in Parkinson's disease.
    Luquin MR; Obeso JA; Martínez-Lage JM; Tresguerres J; Parada J; Nieuweboer B; Dorow R; Horowski R
    Adv Neurol; 1987; 45():561-8. PubMed ID: 3825733
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
    Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
    Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lisuride in Parkinson disease].
    Leiguarda R; Micheli F; Fernández Pardal M
    Medicina (B Aires); 1985; 45(1):29-34. PubMed ID: 3880105
    [No Abstract]   [Full Text] [Related]  

  • 19. Terguride: partial dopamine agonist in the treatment of Parkinson's disease.
    Brücke T; Danielczyk W; Simányi M; Sofic E; Riederer P
    Adv Neurol; 1987; 45():573-6. PubMed ID: 3825735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lisuride in the treatment of Parkinson syndrome].
    Filipová M; Roth B; Kás S; Macek Z; Rozsíval V; Karen P; Votavová M; Krejcová H
    Cesk Neurol Neurochir; 1987 Mar; 50(2):102-7. PubMed ID: 3581244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.